Literature DB >> 20638089

Pharmacokinetics of tulathromycin following subcutaneous administration in meat goats.

Gabrielle Young1, Geof W Smith, Teresa L Leavens, Scott E Wetzlich, Ronald E Baynes, Sharon E Mason, Jim E Riviere, Lisa A Tell.   

Abstract

Tulathromycin is a triamilide antibiotic that maintains therapeutic concentrations for an extended period of time. The drug is approved for the treatment of respiratory disease in cattle and swine and is occasionally used in goats. To investigate the pharmacokinetics of tulathromycin in meat goats, 10 healthy Boer goats were administered a single 2.5 mg/kg subcutaneous dose of tulathromycin. Plasma concentrations were measured by ultra-high pressure liquid chromatography tandem mass spectrometry (UPLC-MS/MS) detection. Plasma maximal drug concentration (Cmax) was 633 ± 300 ng/ml (0.40 ± 0.26 h post-subcutaneous injection). The half-life of tulathromycin in goats was 110 ± 19.9 h. Tulathromycin was rapidly absorbed and distributed widely after subcutaneous injection 33 ± 6 L/kg. The mean AUC of the group was 12,500 ± 2020 h ng/mL for plasma. In this study, it was determined that the pharmacokinetics of tulathromycin after a single 2.5 mg/kg SC injection in goats were very similar to what has been previously reported in cattle.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638089     DOI: 10.1016/j.rvsc.2010.06.025

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  4 in total

1.  Caprine abscess model of tulathromycin concentrations in interstitial fluid from tissue chambers inoculated with Corynebacterium pseudotuberculosis following subcutaneous or intrachamber administration.

Authors:  K E Washburn; V R Fajt; S D Lawhon; L G Adams; L A Tell; W T Bissett
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

2.  Estimation of tulathromycin depletion in plasma and milk after subcutaneous injection in lactating goats using a nonlinear mixed-effects pharmacokinetic modeling approach.

Authors:  Zhoumeng Lin; Matthew Cuneo; Joan D Rowe; Mengjie Li; Lisa A Tell; Shayna Allison; Jan Carlson; Jim E Riviere; Ronette Gehring
Journal:  BMC Vet Res       Date:  2016-11-18       Impact factor: 2.741

3.  Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.

Authors:  Yongda Zhao; Li-Li Guo; Binghu Fang; Baotao Liu
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

4.  Tulathromycin treatment does not affect bacterial dissemination or clearance of Brucella melitensis 16M following experimental infection of goats.

Authors:  Paola M Boggiatto; Steven C Olsen
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.